Alvogen’s subsidiary in Taiwan, Lotus Pharmaceuticals, has formed capital and business collaboration agreements with Fuji Pharma in Japan. Under the terms of the agreement, Fuji has acquired a two percent stake in Lotus for approximately $20 million. Lotus has also acquired 3.9% stake in Fuji for an equal sum.   The transaction is designed to strengthen Lotus and Fuji’s commercial platform in Japan and other Asian pharmaceutical markets, to explore cross-selling opportunities, realize synergies ...